Macrophage activation syndrome by COVID-19 in the adult
DOI:
https://doi.org/10.32818/reccmi.a6n1a2Keywords:
COVID-19, SARS-CoV-2, cytoquine storm, macrophage, inflammation.Abstract
The COVID-19 infection has a heterogenous disease course. It may be asymptomatic or paucisymptomatic. However, immunologic complications such as macrophage activation síndrome, resulting in cytokine storm syndrome, and acute respiratory distress syndrome, may also occur in some patients.
We describe an atypical case of a 38-year-old man admitted to study in clinical suspicion of lymphoproliferative síndrome, whose final diagnosis was macrophage activation syndrome by COVID-19 infection without respiratory symptoms and an arterial thrombotic splenic event associated.
Downloads
Metrics
References
Otsuka R, Seino KI. Macrophage activation syndrome and COVID-19. Inflamm Regen. 2020; 40: 19. https://doi.org/10.1186/s41232-020-00131-w.
McGonagle D, Sharif K, O'Regan A. The Role of Cytokines including Interleukin-6 in COVID-19 induced Pneumonia and Macrophage Activation Syndrome-Like Disease. Autoimmun Rev. 2020; 19(6): 102537. https://doi.org/10.1016/j.autrev.2020.102537.
Quirch M, Lee J, Rehman S. Hazards of the Cytokine Storm and Cytokine-Targeted Therapy in Patients With COVID-19: Review. J Med Internet Res. 2020; 22(8): e20193. https://doi.org/10.2196/20193.
Paces J, Strizova Z, Smrz D, Cerny J. COVID-19 and the immune system. Physiol Res. 2020; 69(3): 379-388. https://doi.org/10.33549/physiolres.934492.
Whittaker E, Bamford A, Kenny J, Kaforou M, Jones CE, Shah Pet al; PIMS-TS Study Group and EUCLIDS and PERFORM Consortia. Clinical Characteristics of 58 Children With a Pediatric Inflammatory Multisystem Syndrome Temporally Associated With SARS-CoV-2. JAMA. 2020; 324(3): 259-269. https://doi.org/10.1001/jama.2020.10369.
Soy M, Keser G, Atagündüz P. Cytokine storm in COVID-19: pathogenesis and overview of anti-inflammatory agents used in treatment. Clin Rheumatol. 2020; 39(7): 2085-2094. https://doi.org/10.1007/s10067-020-05190-5.
Mehta P, Porter JC, Manson JJ, Isaacs JD, Openshaw PJM, McInnes IB et al. Therapeutic blockade of granulocyte macrophage colony-stimulating factor in COVID-19-associated hyperinflammation: challenges and opportunities. Lancet Respir Med. 2020; 8(8): 822-830. https://doi.org/10.1016/S2213-2600(20)30267-8.
Siemieniuk RA, Bartoszko JJ, Ge L, Zeraatkar D, Izcovich A, Kum E et al. Drug treatments for covid-19: living systematic review and network meta-analysis. BMJ 2020; 370: m2980. https://doi.org/10.1136/bmj.m2980.
Published
How to Cite
Issue
Section
License
Copyright (c) 2021 Lorena Salmerón-Godoy, Adrián López-Alba, Elena Arranz-Canales
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Permite compartir, copiar y redistribuir el material en cualquier medio o formato, bajo los siguientes términos:
Reconocimiento: debe otorgar el crédito correspondiente, proporcionar un enlace a la licencia e indicar si se realizaron cambios. Puede hacerlo de cualquier manera razonable, pero no de ninguna manera que sugiera que el licenciante lo respalda a usted o su uso.
No comercial: no puede utilizar el material con fines comerciales.
No Derivados: si remezcla, transforma o construye sobre el material, no puede distribuir el material modificado.
Sin restricciones adicionales: no puede aplicar términos legales o medidas tecnológicas que restrinjan legalmente a otros de hacer cualquier cosa que permita la licencia.
